Serum MG53/TRIM72 Is Associated With the Presence and Severity of Coronary Artery Disease and Acute Myocardial Infarction

Abstract

Background: Mitsugumin 53 or Tripartite motif 72 (MG53/TRIM72), a myokine/cardiokine belonging to the tripartite motif family, can protect the heart from ischemic injury and regulate lipid metabolism in rodents. However, its biological function in humans remains unclear. This study sought to investigate the relationship between circulating MG53 levels and coronary artery disease (CAD).Methods: The concentration of MG53 was measured by enzyme-linked immunosorbent assay (ELISA) in serum samples from 639 patients who underwent angiography, including 205 controls, 222 patients with stable CAD, and 212 patients with acute myocardial infarction (AMI). Logistic and linear regression analyses were used to analyze the relationship between MG53 and CAD.Results: MG53 levels were increased in patients with stable CAD and were highest in patients with AMI. Additionally, patients with comorbidities, such as chronic kidney disease (CKD) and diabetes also had a higher concentration of MG53. We found that MG53 is a significant diagnostic marker of CAD and AMI, as analyzed by logistic regression models. Multivariate linear regression models revealed that serum MG53 was significantly corelated positively with SYNTAX scores. Global Registry of Acute Coronary Events (GRACE) scores also correlated with serum MG53 levels, indicating that MG53 levels were associated with the severity of CAD and AMI after adjusting for multiple risk factors and clinical biomarkers.Conclusion: MG53 is a valuable diagnostic marker whose serum levels correlate with the presence and severity of stable CAD and AMI, and may represent a novel biomarker for diagnosing CAD and indicating the severity of CAD.

Alkylation Repair Homolog 5 Regulates N(6)-methyladenosine (m6A) Methylation of Mitsugumin 53 to Attenuate Myocardial Infarction by Inhibiting Apoptosis and Oxidative Stress

“…27,28 MG53 is highly expressed in patients with MI and has heart protection functions. 13 Upregulation of MG53 inhibits cardiomyocyte oxidative stress, inflammation, and apoptosis. 29,30 Here, we identified that MG53 expression was decreased in MI.…”

“…12 The expression of MG53 is highest in patients with MI among coronary artery disease and is identified as a diagnosis biomarker. 13 Moreover, MG53 inhibits hypoxia/ reoxygenation or I/R-induced myocardial injury. 14 However, whether MG53 can be modified by m6A methylation is unknown.…”

TRIM21 aggravates cardiac injury after myocardial infarction by promoting M1 macrophage polarization

“…For example, the upregulation of TRIM44 by non‐coding RNA hypoxia‐inducible factor 1α (HIF1A) ‐antisense RNA 2 (HIF1A‐AS2) is associated with cardiac cell apoptosis, migration, and invasion in hypoxia-treated human cardiomyocytes ( 35 ). TRIM72 levels are increased in MI and are positively related to Global Registry of Acute Coronary Events (GRACE) scores ( 36 ). Moreover, TRIM72 deficiency exacerbates ischemia-reperfusion injury (I/R)-induced myocardial damage, and overexpression of TRIM72 alleviates cardiac dysfunction after MI ( 37 , 38 ).…”

Protective role of MG53 against ischemia/reperfusion injury on multiple organs: A narrative review

“…Logistic and linear regression was used to analyze the relationship between MG53 and coronary heart disease. They found that patients with stable cardiovascular disease and acute myocardial infarction had elevated serum MG53 levels ( Xie et al, 2020a ), and subsequent studies have shown that MG53 is a valuable prognostic indicator for patients with acute myocardial infarction (AMI) ( Xie et al, 2020b ), which can provide new ideas for clinical practice.…”